Replek is a pharmaceutical company with a strong export orientation and global presence. As much as 75% of total production is intended for export, which is a clear confirmation of the competitiveness, trust and quality of our products on international markets.
Replek has obtained the EU GMP certificate for the fifth time, confirming our commitment to:
Through long-term partnerships, a strategic approach and responsible corporate governance, we are continuously expanding our presence in Europe, the CIS region, the Middle East, Africa, Asia and other selected markets.
Our international strategy is based on sustainable growth, trust and long-term market development.
Replek products are available in more than 25 international markets.
Poland, Lithuania, United Kingdom.
Serbia, Albania, Kosovo, Bosnia and Herzegovina, Montenegro.
Iraq, Libya.
Russia, Belarus, Turkmenistan, Moldova, Azerbaijan, Kyrgyzstan, Tajikistan, Uzbekistan, Georgia, Kazakhstan, Armenia.
Vietnam.
Strengthening the presence in the markets across European Union through regulatory compliance and portfolio expansion
Strengthening partnerships in the CIS region
Expanding of the portfolio of medical cannabis-based products in selected European markets
Expanding collaborations in private labels and contract manufacturing
Our goal is to further strengthen Replek's position as a reliable, high-quality, and long-term pharmaceutical partner.
We are open to cooperation in the area of:
Distribution of pharmaceutical products
01Out – Licensing agreements
02Contract manufacturing services
03Collaboration in the field of medical cannabis-based products
04Joint development and strategic projects (Private and white label).
05Replek's international portfolio includes a board range of pharmaceutical products, developed and manufactured according to the highest quality standards.
We build partnerships founded on trust, quality, and long-term vision – because to us, growth means stability, responsibility, and shared success.
